1. Formulation, optimisation, and evaluation of Lornoxicam-loaded Novasomes for targeted ulcerative colitis therapy: in vitro and in vivo investigations.
- Author
-
Darwish, Asmaa Badawy, Salama, Abeer, and Essam Ibrahim Al-Samadi, Inas
- Subjects
- *
SURFACE active agents , *ULCERATIVE colitis , *ZETA potential , *TOLL-like receptors , *OLEIC acid - Abstract
AbstractThe purpose of this work was to create and assess Lornoxicam (LOR) loaded Novasomes (Novas) for the efficient treatment of ulcerative colitis. The study was performed using a 23 factorial design to investigate the impact of several formulation variables. Three separate parameters were investigated: Surface Active agent (SAA) type (
X1 ), LOR concentration (X2 ), and SAA: Oleic acid ratio (X3 ). The dependent responses included encapsulation efficiency (Y1 : EE %), particle size (Y2 : PS), zeta potential (Y3 : ZP), and polydispersity index (Y4 : PDI). The vesicles demonstrated remarkable LOR encapsulation efficiency, ranging from 81.32 ± 3.24 to 98.64 ± 0.99%. The vesicle sizes ranged from 329 ± 9.88 to 583.4 ± 9.04 nm with high negative zeta potential values. The release pattern for Novas’ LOR was biphasic and adhered to Higuchi’s model. An in-vivo study assessed how LOR-Novas affected rats’ acetic acid-induced ulcerative colitis (UC). The optimised LOR-Novas effectively reduced colonic ulceration (p < 0.05) and reduced the inflammatory pathwayvia inhibiting Toll-like receptor 4 (TLR4), Nuclear factor kappa β (NF-κβ) and inducible nitric oxide (iNO). At the same time, it elevated Silent information regulator-1(SIRT-1) and reduced glutathione (GSH) colon contents. Thus, the current study suggested that the formulation of LOR-Novas may be a viable treatment for ulcerative colitis. [ABSTRACT FROM AUTHOR]- Published
- 2025
- Full Text
- View/download PDF